A practical reference on regulatory status: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-11-14 and is reviewed periodically as new material appears.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
Identity testing for a cyclic peptide of this size usually relies on reversed-phase high-performance liquid chromatography coupled to mass spectrometry. The mass spectrum confirms molecular weight, while the chromatographic trace indicates the proportion of related impurities. Tandem mass spectrometry can provide sequence-level information when fragmentation data are compared against a reference standard. Nuclear magnetic resonance is sometimes used to confirm the lactam bridge, although it requires more material and greater operator expertise than routine chromatographic methods.
Lyophilised peptide powder is comparatively stable when kept dry, cold and protected from light. Once dissolved, the molecule is exposed to hydrolysis, oxidation and microbial growth, and degradation accelerates at higher temperatures and in alkaline solution. Repeated freeze-thaw cycles concentrate solutes and promote aggregation. Handling guidance for research peptides commonly clusters around freezer temperatures for powder and short refrigerated use for reconstituted solutions, with pH control and sterile technique applied throughout.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Analogue of alpha-melanocyte-stimulating hormone |
| Common synonyms | MT-II; melanotan 2 | No internationally accepted non-proprietary name |
| Typical presentation | Lyophilised powder in a sealed vial | Often supplied alongside a separate diluent |
| Regulatory status | Unapproved therapeutic substance | Customs seizure reported in several jurisdictions |
| Reported route in use | Subcutaneous injection | Self-administered outside clinical settings |
Melanotan II is a synthetic cyclic heptapeptide with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, corresponding to a molecular formula of C50H69N15O9 and a monoisotopic mass near 1024 daltons. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, a peptide hormone produced by cleavage of proopiomelanocortin. A lactam bridge between the aspartate and lysine side chains closes the ring, and the C-terminal amide removes a free carboxyl group. Both modifications increase resistance to enzymatic degradation compared with the linear parent hormone. Four substitutions distinguish it from afamelanotide, the linear analogue studied under the name melanotan I.
Receptor-binding studies classify melanotan II as a non-selective melanocortin agonist. It interacts with MC1R, MC3R, MC4R and MC5R, with reported affinities in the low nanomolar range and no strong subtype preference. Activation of MC1R on dermal melanocytes shifts pigment synthesis toward eumelanin, the dark polymer deposited in melanosomes and transferred to keratinocytes. Because the same peptide engages MC4R in the hypothalamus, it also appears in animal work on food intake and erectile response, which is why it is discussed in both pigment and metabolic research. Which receptor populations dominate after systemic exposure in humans is not fully established.
Published pharmacokinetic information is limited and comes mainly from small studies rather than registrational trials. Plasma half-life is usually described as short, on the order of tens of minutes, followed by rapid tissue distribution and clearance of the intact peptide. Metabolites and low concentrations of parent compound have been reported in urine, a detail relevant to anti-doping and forensic testing. Whether repeated exposure changes receptor sensitivity or clearance over time remains an open question. Values differ noticeably between analytical assays, so published numbers should be read as approximate rather than definitive.
The peer-reviewed record is dominated by small early-phase studies, case reports and pharmacovigilance summaries rather than large randomised trials. Papers typically examine tanning response, receptor selectivity or patterns of reported adverse events. Many note that participants obtained the peptide outside a clinical setting, which limits verification of composition and administered amount. Reported events vary widely, and causality is frequently unclear because the identity and purity of self-sourced material are unknown. Open questions include whether repeated melanocortin receptor stimulation produces cumulative effects, and how often label claims match actual content.
Identification in laboratories relies on reversed-phase liquid chromatography coupled with tandem mass spectrometry, with product-ion spectra compared against a certified reference standard. High-resolution mass spectrometry supplies accurate mass confirmation, and peptide mapping after enzymatic digestion separates melanotan II from closely related analogues. Quantitation of seized material is complicated by unknown counter-ions and residual trifluoroacetate left from purification. Immunoassays raised against alpha-melanocyte-stimulating hormone can cross-react, so chromatographic confirmation is normally required. Urinary detection windows are short, and reported limits of detection differ substantially between laboratories.
The compound was developed in the late 1980s and early 1990s by academic researchers investigating melanocortin signaling and pigmentation. Early work explored whether synthetic analogs could reproduce effects of the natural hormone under controlled conditions. The molecule never advanced through the full regulatory pathway required for approval as a medicine. From the mid-2000s onward it appeared in unregulated consumer markets, often distributed through informal channels. That gap between research origins and commercial availability shapes how the compound is discussed today.
Melanotan-2 is a synthetic peptide designed as an analog of alpha-melanocyte-stimulating hormone, a signaling molecule produced in the pituitary and skin. Its structure is a linear chain of seven amino acids that folds into a ring through an internal lactam bridge joining two side chains. The compound is sometimes written as MT-II or MEL-2 in informal and commercial contexts. It belongs to the melanocortin peptide family, a group of short signaling molecules that share a conserved core sequence recognized by melanocortin receptors.
Two structural changes distinguish the synthetic peptide from the natural hormone. A norleucine residue replaces methionine at one position, and a D-configured phenylalanine replaces the natural L-form at another. Both substitutions slow enzymatic breakdown, which extends the molecule's persistence relative to the parent hormone. The lactam bridge further constrains the backbone into a stable conformation. These features are standard design strategies in peptide chemistry and are not unique to this compound; they appear across many research peptides built for improved stability.
Published research on the compound remains limited. Much of the human data comes from small, early-stage studies rather than large controlled trials, and several questions about effects and variability between individuals remain open. Investigators have examined receptor activity, pigment pathways, and related physiological responses in laboratory and animal models. Findings from those models do not automatically translate to human outcomes. Reviews frequently note the scarcity of rigorous clinical evidence and call for better-characterized study material.
Because the substance circulates mainly through informal markets, verification is a recurring theme in technical discussion. Independent analyses have found that labeled content and actual content can diverge, and that purity varies between samples. Analytical laboratories use reversed-phase chromatography to separate components and mass spectrometry to confirm identity. Isotope-labeled internal standards improve quantification in complex matrices. Such methods describe what a sample contains but say nothing about its sterility, lawful status, or suitability for any use. Open questions remain about how consistently testing is applied across the supply chain.
== External links == Ernest Beutler (1928–2008) – Profile, including an oral history, from The American Society of Hematology. Scientific Publications – All publications of articles by Ernest Beutler listed in PubMed. Marshall A. Lichtman, "Ernest Beutler", Biographical Memoirs of the National Academy of Sciences (2012)
In December 2025, the US began blockading Venezuelan waters and directly targeting Venezuelan oil tankers. Special forces launched from USS Gerald R. Ford seized a tanker off the coast of Venezuela on 10 December 2025. The US planned additional seizures of vessels transporting Venezuelan crude, imposed additional sanctions on Maduro's family and Venezuelan oil shipments, Trump demanded the return of nationalized oil and land resources he said were seized from US corporations by the Chávez government in 2007, and announced the US would designate the "Maduro regime" a Foreign Terrorist Organization.
== Formulation of the rule == This rule is derived from the fact that, perhaps coincidentally, for the most common chemical elements in neutral organic compounds (hydrogen, carbon, nitrogen, oxygen, silicon, phosphorus, sulfur, and the halogens), elements with even numbered nominal masses form even numbers of covalent bonds, while elements with odd numbered nominal masses form odd numbers of covalent bonds, with the exception of nitrogen, which has a nominal (or integer) mass of 14, but has a valency of 3. The nitrogen rule is only true for neutral structures in which all of the atoms in the molecule have a number of covalent bonds equal to their standard valency (counting each sigma bond and pi bond as a separate covalent bond for the purposes of the calculation). Therefore, the rule is typically only applied to the molecular ion signal in the mass spectrum. Mass spectrometry generally operates by measuring the mass of ions. If the measured ion is generated by creating or breaking a single covalent bond (such as protonating an amine to form an ammonium center or removing a hydride from a molecule to leave a positively charged ion) then the nitrogen rule becomes reversed (odd numbered masses indicate even numbers of nitrogens and vice versa). However, for each consecutive covalent bond that is broken or formed, the nitrogen rule again reverses.
Sources: en.wikipedia.org
Protein purification is a series of processes intended to isolate one or a few proteins from a complex mixture, usually cells, tissues, or whole organisms. Protein purification is vital for the specification of the function, structure, and interactions of the protein of interest. The purification process may separate the protein and non-protein parts of the mixture, and finally separate the desired protein from all other proteins. Ideally, to study a protein of interest, it must be separated from other components of the cell so that contaminants will not interfere in the examination of the protein of interest's structure and function. Separation of one protein from all others is typically the most laborious aspect of protein purification. Separation steps usually exploit differences in protein size, physico-chemical properties, binding affinity, and biological activity. The pure result may be termed protein isolate.
Nuclear medicine is the use of open radionuclides for diagnostic and therapeutic purposes (radionuclide therapy). It also includes the use of other radioactive substances and nuclear physics techniques for functional and localization diagnostics. George de Hevesy (1885-1966) lived as a lodger and in 1923 suspected that his landlady was offering him pudding that he had not eaten the following week. He mixed a small amount of a radioactive isotope into the leftovers. When she served him the pudding a week later, he was able to detect radioactivity in a sample of the casserole. When he showed this to his landlady, she immediately gave him notice. The method he used made him the father of nuclear medicine. It became known as the tracer method, which is still used today in nuclear medicine diagnostics. A small amount of a radioactive substance, its distribution in the organism, and its path through the human body can be tracked externally. This provides information about various metabolic functions of the body. The continuous development of radionuclides has improved radiation protection. For example, the mercury compounds 203chloro-merodrin and 197chloro-merodrin were abandoned in the 1960s as substances were developed that allowed a higher photon yield with less radiation exposure. Beta emitters such as 131I and 90Y are used in radionuclide therapy. In nuclear medicine diagnostics, the beta+ emitters 18F, 11C, 13N, and 15O are used as radioactive markers for tracers in positron emission tomography (PET).
JEOL, Ltd. (日本電子, Nihon Denshi Kabushiki-kaisha; Nihon meaning Japan and Denshi meaning electron) is a major developer and manufacturer of electron microscopes and other scientific instruments, industrial equipment and medical equipment. Its headquarters are in Tokyo, Japan, with 25 domestic and foreign subsidiaries and associated companies as of 2014. It is listed in the top ten businesses worldwide for analytical laboratory instrument manufacturing. It has been included in the Activest Lux Nanotech Mutual Fund and the WestLB Nanotech Fund.
Sources: en.wikipedia.org
The secret behind a spider web's stickiness lies in the tiny glue droplets dotting its silk threads. Orb-weaver spiders, such as Larinioides cornutus, coat their silk with a special hygroscopic substance that keeps the glue soft and tacky by drawing in water from the air. This built-in humidity control prevents the adhesive from drying out too quickly. The hardening of the viscoelastic protein is indirectly controlled by changes in water content, which in turn affect the concentration of the ionic liquid. As this balance shifts, the glue's viscosity adjusts, helping the web maintain its grip on captured prey. The web is electrically conductive which causes the silk threads to spring out to trap their quarry, as flying insects tend to gain a static charge which attracts the silk. Neurotoxins have been detected in the glue balls of some spider webs. Presumably these toxins help immobilize prey, but their function could also be antimicrobial, or protection from ants or other animals that steal from the webs or might attack the spider. Spider silk has greater tensile strength than the same weight of steel and much greater elasticity. Its microstructure is under investigation for potential applications in industry, including bullet-proof vests and artificial tendons. Researchers have used genetically modified mammals and bacteria to produce the proteins needed to make this material.
== Primary chloroplast lineages == All primary chloroplasts belong to one of four chloroplast lineages—the glaucophyte chloroplast lineage, the rhodophyte ("red") chloroplast lineage, the chloroplastida ("green") chloroplast lineage, and the amoeboid Paulinella chromatophora lineage. The glaucophyte, rhodophyte, and chloroplastidian lineages are all descended from the same ancestral endosymbiotic event and are all within the group Archaeplastida.
Dingell indicated that she planned to run for her husband's congressional seat after he announced his retirement. On August 5, she won the Democratic primary, winning 77.7% of the vote against Raymond Mullins. On November 4, she won the general election, defeating Republican Terry Bowman with 65.0% of the vote. When Dingell was sworn in, she became the first U.S. non-widowed woman in Congress to succeed her husband. His father, John Dingell Sr., held Michigan's 12th district for 22 years before his son won it. Altogether, the Dingells had represented this district, numbered as the 15th from 1933 to 1965, the 16th from 1965 to 2003, the 15th again from 2003 to 2013, and the 12th from 2013 to 2023, since 1932.
== Distribution == Mealworms most-likely originated in the Mediterranean region, but are now present in many areas of the world as a result of human trade and colonization. The oldest archaeological records of mealworms can be traced to Bronze Age Turkey. Records from the British Isles and northern Europe are from a later date, and mealworms are conspicuously absent from archaeological finds from ancient Egypt.
Sources: en.wikipedia.org
No. No major regulatory agency has granted a marketing authorisation for melanotan II as a medicine. Products sold under this name are generally presented as laboratory reagents and are not subject to the batch-release testing applied to approved drugs.
It was developed in the 1980s by researchers investigating analogues of alpha-melanocyte-stimulating hormone for pigmentation and related endpoints. Early work included small human studies during the 1990s. Development did not progress to licensing, and the compound remained a research and grey-market item.
Peptides are prone to truncation, oxidation and aggregation during synthesis and handling. Without independent testing, a buyer cannot confirm the identity or the content of a vial. Analytical surveys of unapproved peptide products have repeatedly found discrepancies between label claims and measured composition.
Mass spectrometry combined with liquid chromatography provides both molecular weight confirmation and a measure of related impurities. Tandem mass spectrometry adds sequence information. A purity percentage reported without a mass measurement does not confirm what the material is.